Quotient Clinical’s new GMP facility in Nottingham, UK will include added spray drying capacity for spray drying of batches up to 2 kilograms. The facility is scheduled to open later this year. Quotient Clinical’s inhaled drug development work has included a partnership with Pulmatrix on its PUR0200 DPI.
Quotient Clinical VP of Pharmaceutical Sciences Nikki Whitfield said, “Poor solubility is increasingly prevalent in drug pipelines across the industry. We have established a broad suite of formulation approaches within our Translational Pharmaceutics platform to address these complex solubility and bioavailability challenges, and this latest investment will allow us to efficiently scale up the production of optimized formulations to support our clients’ downstream clinical development programs.”
Read the Quotient Clinical press release.
